Pharma Focus Asia
KP - Sustainable Packaging Solutions

Genentech Developed Breakthrough Therapy Venclexta for Myelodysplastic Syndromes

Genentech developed Venclexta in combination with Azacitidine for the treatment of patients with Myelodysplastic Syndromes.

Venclexta® in combination with Azacitidine has the ability to treat adult patients who have formerly untreated with intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the revised International Prognostic Scoring System (IPSS-R).

Venclexta, first-in-class targeted therapy produced to bind and inhibit the B-cell lymphoma-2 (BCL-2) protein.In some blood cancers and tumors it is noticed that BCL-2 builds up and restricts cancer cells from dying or self-destructing, which is known as apoptosis.

Some of the side effects of Venclextain combination with Azacitidine results in lowering white blood cell count, diarrhea, shortness of breath, tiredness, cough, muscle and joint pain, vomiting, dizziness, sore throat and low blood pressure.

Myelodysplastic Syndromes (MDS) are group of blood cancers causing weakness, anemia, frequent infections, and debilitating fatigue affecting the person’s quality of life. It affects the ability of the bone marrow to produce normal blood cells. In few cases, MDS may also lead to acute myeloid leukemia (AML).

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD)Venclexta® (venetoclax) in combination with azacitidine for the treatment of Myelodysplastic Syndromes.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?